2018 年度報告
|
|
|
- 寡没 步
- 4 years ago
- Views:
Transcription
1 2018 年度報告
2
3 FCISFCS Vistra Corporate Services (HK) Limited Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley Thomas Malley Scott A. Samuels Mourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY Cayman Islands Ranjeev Krishana 30 Donald W. Glazer Michael Goller
4 Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY Cayman Islands Mourant Ozannes
5 2018 4
6 Zanubrutinib (BGB-3111) (BTK) BTK 2018 (R/R)(MCL)(CLL)(SLL) R/R MCL R/R CLL/SLL (FDA)(NDA) (WM)zanubrutinibWM MCL zanubrutinib Tislelizumab (BGB-A317) 1(PD-1) FcIgG (chl) tislelizumab(ubc)
7 Pamiparib (BGB-290) 1(PARP1) PARP2 3 lifirafenib(bgb-283)(raf)bgb-a333 PD-L1BGB-A425TIM-3 sitravatinibmirati Therapeutics, Inc. (Mirati) ZW25 ZW49Zymeworks Inc. (Zymeworks)HER ABRAXANE REVLIMID avadomide (CC-122) Cereblon tislelizumab (NMPA) (NRDL)
8 BTKZanubrutinibZanubrutinibBTK 2 3 BTK zanubrutinib TislelizumabPD- 1 PD-L1 tislelizumab
9 Mirati Zymeworks
10 zanubrutinib (BTK) tislelizumab (PD-1) pamiparib lifirafenib (RAF Dimer) BGB-A333 (PD-L1) BGB-A425 (TIM-3) REVLIMID ABRAXANE (IMiD) VIDAZA avadomide (CC-122, CELMoD) NHL sitravatinib ZW25 * ** ***REVLIMID 1. tislelizumab2. Mirati Therapeutics, Inc.APAC 3. Zymeworks 1L2L3LAMLCLLCMMoL DLBCLB Dose EscESCC FLgBRCA BRCAGCHCCHLIMiD MCLMDSMMMZL NSCLCNDNDANHLNK OCPHR/RRTSLLSq TMZUCWM
11 Zanubrutinib (BGB-3111)BTK Zanubrutinib BTKZanubrutinib BTKIMBRUVICA BTK1 24 BTK BTK B BCR BTKBCRBTKB ZanubrutinibBTK (NHL)(HL) BTB 85%B (SEER)201772,24020,140 20,1104,660SEER 3,000 1,350Chen et al, Cancer Statistics in China, 2015CA Cancer J. Clin, (2):115-32Chen et al GLOBOCAN 88,200 93,09752,100 50,86590%4.5%
12 CD20B BTK PI3Kidelalisibcopanlisibduvelisib Bcl-2venetoclax YESCARTA (axicabtagene ciloleucel)b YESCARTA CD19T BTKIMBRUVICA p CD20 obinutuzumabrituximab BTK 45BTKCALQUENCE (acalabrutinib) BTK zanubrutinib1,300zanubrutinib zanubrutinib1 zanubrutinibb zanubrutinib40 24 BTKBTK
13 (IWWM) ( )>PR 85 (55-749)62ORR 92%(67/73)(MRR)82%41%(VGPR) IgM>90% CT12 (PFS)89% IgM32.7g/L( )8.2g/L( )32<10g/ dl 8.85g/dL( ) 13.4g/dL( ) 63 MYD88MYD88L265Pn 5494% 89%46%MYD88WT BTK89%67% 22% Zanubrutinibzanubrutinib (AE)(43%) (42%)(17%)(17%)(16%)(16%)(16%) 3-4(9%)(7%)(5%) (5%)(4%)(4%)(SAE)32 (42%)(7%) zanubrutinib (12%) (5%)(3%)(5%)
14 zanubrutinib zanubrutinib160mg %2% 39% 40% zanubrutinib TN51 R/R 6616 TN 50 R/R %(62/66) 3%2/66)82%(54/66)9%(6/66) 5%(3/66)(SD)12 TN %(16/16)6%1/16) 81%(13/16)13%(2/16)R/R %(46/50) 2%1/50)82%(41/50)8%(4/50)6%(3/50) Zanubrutinib ( 10%)(46%)(29%)(28%)(23%) (22%)(19%)(15%)(13%)(13%)(12%)(12%) (12%)
15 zanubrutinib 2 zanubrutinib mg zanubrutinib (IRC) Lugano2014PET (75.6%) 35.9 ( )IRC 83.5%(71/85)58.8%(50/85)24.7%(21/85)24 82%24.1 ( )(DOR) 90%24 ZanubrutinibB (AE) (31.4%)(29.1%) (29.1%)(22.1%)5% AE (11.6%)(5.8%)(4.7%)(TEAE) BTK (10.5%)(1.2%) CNS 1 zanubrutinibb n 9n 39)12.7( ) Lugano % (40/45)26.7%12/45)62.2%(28/45) CTPET ( )
16 ZanubrutinibB (33.3%)(33.3%) (29.2%)(25.0%)(18.8%)56.3% (8.3%)(6.3%)(6.3%) (6.3%)(6.3%)(6.3%)(6.3%)18.8% zanubrutinib zanubrutinib B n (1-8) 2(1-8) 3 (1-9) 2 (1-10) 78% 41% 42% 31% % 18% 8% 15% 78% 24% 35% 15% MR Tam et al.(poster 1592)
17 Zanubrutinib (EHA) EHA zanubrutinibb 476 zanubrutinibbtkzanubrutinib BTK (2%)(2%) 3 (1%)zanubrutinib(3%)(94%) (14%)(7%) (7%)116(24%)38 (8%)zanubrutinib (6%)(1%)(1%) 1%(2%)(PJP) (CMV)(26%)(11%) (2%)n 3CNS5 1.2n 8 n 2n 2n 1 614%1219%18 21% (3%)(1%) zanubrutinib zanubrutinib3 3 3 GAZYVA
18 zanubrutinib zanubrutinib zanubrutinib zanubrutinibzanubrutinib B 2 Tislelizumab (BGB-A317)PD-1 TislelizumabPD-1 tislelizumab T(CTL) T PD-1T PD-L1PD-1 PD-1PD-L1 T PD-L1PD-L1T PD-1PD-1 TislelizumabPD-1PD-L1 PD-L2 PD-1tislelizumab PD-1 PD-1FcFc T
19 PD-1 PD-L1KEYTRUDA (pembrolizumab)opdivo (nivolumab)tecentriq (atezolizumab) IMFINZI (durvalumab)bavencio (avelumab) LIBTAYO (cemiplimab)tislelizumabpd-1 PD-L1 PDR-001Tesaro TSR042PF MEDI PD-1OPDIVO (nivolumab) KEYTRUDA (pembrolizumab)tuoyi (toripalimab)tyvyt (sintilimab) PD-L1PD-1 PD-L PD-1 PD-L PD-1 PD-L1 Globocan 37%44%47% 54%Chen et al PD-1Chen et al. 2016PD SEER PD PD ,200tislelizumab 1 tislelizumab
20 tislelizumab 2 zanubrutinib 2 70 (ASCT) 200 mgzanubrutinib (ORR)(IRC)Lugano2014PET (75.7%) ( ) IRC 85.7%(60/70) 61.4%(43/70) 24.4%(17/70)92.3%(12/13) (69.2%)84% 80% TEAE(52.9%)(30.0%) (28.6%)(27.1%)(17.1%)(14.3%)(14.3%) TEAE21.4%(2.9%)(2.9%) (5.7%)TEAEn 2n 1 n 1TEAE5% (18.6%)(5.7%)(5.7%)
21 tislelizumab dmmr (30-339) 71 (29-540) 4.1 ( ) 2.2 ( ) 4.9 ( ) 5.2 ( ) 10.8 ( ) 11.2 ( ) 4.4 ( ) 8.5 NR NR ( ) N 54 N 54 N 17 N 50 N 49 N 17 N 46 N * * A/1B2018Sanjeev Horvath Meniawy /22018Shahneen
22 tislelizumab tislelizumab 38% 10% 1a 1b N 116 n (%) N 335 n(%) N 451 n (%) 114 (25.3) 322 (71.4) 436 (96.7) 47 (10.4) 78 (17.3) 125 (27.7) 41 (9.1) 68 (15.1) 109 (24.2) 19 (4.2) 71 (15.7) 90 (20.0) 32 (7.1) 49 (10.9) 81 (18.0) 26 (5.8) 50 (11.1) 76 (16.9) 26 (5.8) 38 (8.4) 64 (14.2) 20 (4.4) 43 (9.5) 63 (14.0) 22 (4.9) 40 (8.9) 62 (13.7) 15 (3.3) 45 (10.0) 60 (13.3) 23 (5.1) 37 (8.2) 60 (13.3) 12 (2.7) 33 (7.3) 45 (10.0) BGB-A317 IB v6.0bgb A317_ (45.0%) % % 183.2%9 2.0% 25%3% 5% 3 16% 37% tislelizumab6% 13%
23 %tislelizumab tislelizumab11 3 tislelizumab tislelizumab 3 3 T NK 2 PD-L1 2 3 tislelizumab tislelizumab Pamiparib (BGB-290)PARP PamiparibPARP1 PARP2 pamiparibparp DNA
24 PARPPARP1 PARP2DNAPARP1 PARP2 DNADNADNA PARPDNADNA DNAPARP BRCA1/2PARP PARPBRCABRCA1/2 (HRD)BRCA BRCA1/2BRCADNA PARPPARPBRCA PARP PARPPARP DNAPARP DNA PARPPARPDNA PARPBRCAPD-1 PD-L
25 PARPPARP PARP SEER201822, ,120164,69026,240 Chen et al ,000272,00060, ,000 PARPLYNPARZA Clovis Oncology RUBRACA (rucaparib) GlaxoSmithKline/Tesaro ZEJULA (niraparib) TALZENNA (talazoparib)veliparib2017parp niraparib PARP fluzoparib PARP pamiparib pamiparib1/ pamiparib1/
26 39(EOC) BRCA BRCA BRCA pamiparib78% 3 10%(56%) (40%)(25%)(21%)(21%)(15%) (12%)46% (DLT) pamiparib 20mg40mg 60mg n 8n 1 BRCA1/2(BRCAm)BRCA 1/2(BRCA-WT) BRCABRCA1/2 BRCAmn 4 BRCA-WTn 2 BRCAmn 1 BRCA- WTn 4(BRCAm) BRCA-WT
27 pamiparib (RP2D)60mgn 12n pamiparib(rt)temozolomidetmz(r/r) (GBM)1b/2 MGMT(O6-methylguanine-DNA methyltransferase) GBM A pamiparib60mg RTR/R GBM C pamiparib60mg28 21 TMZACGBMBRTpamiparib TMZ GBMA n 3,6,9 19 (2-54)18 15 (mrano)(sd) 53.3%95%CI (AE) 5.6%pamiparib RT C mg TMZ20mg TMZ 12.9 ( )15 10 mrano AE(20%)(13.3%)(13.3%)pamiparib TMZ 21 40mg TMZ pamiparib20mg TMZ pamiparib
28 3 2 3 Lifirafenib (BGB-283)RAF LifirafenibRAFLifirafenib BRAF V600EV600E BRAFKRAS/NRAS lifirafenib(mapk)brafbraf KRAS/ NRAS DNAlifirafenib SpringWorks Therapeutics lifirafenib SpringWorks Therapeutics MEKPD RASRAFMAPK 2019 BRAFZELBORAF (vemurafenib)tafinlar (dabrafenib) Array BioPharma BRAFTOVI (encorafenib)braf MEK BRAF V600E/Kdabrafenib MEKINIST (trametinib) Genentech vemurafenib COTELLIC (cobimeditinib) Array Biopharma encorafenib MEKTOVI (binimetinib) BRAF belvarafenib LXH254 Lifirafenib 1 BRAF KRAS/ NRAS 1 lifirafenib BRAF KRAS
29 2017 lifirafenib2 30mg lifirafenib30mgbraf V600 KRAS lifirafenib30mg 1 2 ( 10%)(38.5%)(26.0%) (21.9%)(21.9%)(19.8%)(17.7%)(16.7%) (16.7%)(15.6%)(11.5%)(10.4%)3 4 2% (7.3%)(6.3%)(6.3%)(3.1%)(2.1%) (2.1%)(2.1%)(2.1%)(2.1%) (2.1%)(2.1%)(2.1%) BRAF MEKBRAF V600 V600KV600RBRAF V600 KRAS BRAF V600BRAF V600 BRAF V600EBRAF V600E BRAF V600BRAF MEKBRAF V60013 BRAF V600 KRAS20 KRAS/NRAS 1221KRAS/NRAS10 1aBRAF V600EBRAF V600EKRAS BGB-A333PD-L1 BGB-A333PD-L1PD-1IgG1BGB-A333 tislelizumab BGB-A3331 BGB-A333 tislelizumab
30 BGB-A425TIM-3 BGB-A425T 3TIM-3IgG1 2018BGB-A433 tislelizumab1/2 Sitravatinib (MGCD-0516) Mirati Mirati sitravatinib Sitravatinib RETTAMTYRO3AxlMERVEGFR2KIT Miratisitravatinib 2019sitravatinib3 Mirati sitravatinib CBL Miratisitravatinib 2018sitravatinib tislelizumab 1 Avadomide (CC-122)Cereblon Avadomide(CC-122)Cereblon 1 1/2Avadomide (CC-122) Cereblon avadomide (CC-122) 2018ABRAXANE
31 ABRAXANE ABRAXANE nab ABRAXANE ABRAXANE Chen et al ,60069,500 Her2+ ABRAXANE 3 ABRAXANE TAXOL ANZATAX (TAXOTERE ) (ABRAXANE ) ABRAXANE ABRAXANE
32 REVLIMID REVLIMID 2013 (MM) REVLIMID B B Siegel et al., 2011 IMS 100, :140 Lu et al., 2014IMS , ,000 10, Takeda NINLARO (ixazomib) REVLIMID
33 VIDAZA DNA VIDAZA (MDS) (CMML)20% 30%(AML) Germing et al., ,000100,000 70(NCCN) %DNA DNA DNA 2 (HMAs) % DNA RNA tislelizumab
34 (CRO)(CMO) , zanubrutinib 24, KUBio TM tislelizumab
35 140 (cgmp) zanubrutinibzanubrutinib PD-1tislelizumab (MAH)tislelizumab tislelizumab
36 Celgene Switzerland LLC Celgene Switzerland tislelizumab PD-1 PD-1263Celgene Switzerland % % 12 tislelizumab 1 tislelizumab tislelizumab PD
37 2019(BMS)2019 PD-1OPDIVO (nivolumab) PD-1 tislelizumab PD-1 tislelizumab Celgene Logistics Sàrl Celgene Logistics ABRAXANE REVLIMID VIDAZA avadomide(cc-122) Celgene Logistics REVLIMID Celgene LogisticsCelgene Logistics Celgene Logistics Celgene Logistics ABRAXANE REVLIMID VIDAZA
38 BeiGene (Hong Kong) Co., Ltd.Celgene Holdings East Corporation (PCT) PCT ZanubrutinibPCT zanubrutinibbtkzanubrutinib
39 TislelizumabPCT tislelizumabpd Pamiparib PCT pamiparibparp1/ LifirafenibPCT lifirafenibbraf BRAF 2031 ABRAXANE ABRAXANE REVLIMID REVLIMID VIDAZA VIDAZA
40 ABRAXANE REVLIMID VIDAZA 20 (USPTO) 14 BeiGeneBeiGene
41
42
43
44
45 zanubrutinib
46
47 Hatch-Waxman Amendments Hatch- Waxman Amendments 30Hatch-Waxman Amendments
48 IRAE PD-1tislelizumab IRAE
49 REVLIMID (BLA)
50 REVLIMID
51
52
53
54
55
56
57 ABRAXANE REVLIMID VIDAZA avadomide(cc-122)
58
59 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers
60 tislelizumab
61
62
63
64
65
66
67 ABRAXANE REVLIMID VIDAZA
68
69
70
71 tislelizumab zanubrutinibbtk2027parp pamiparib pamiparib
72
73
74
75
76 tislelizumababraxane REVLIMID VIDAZA
77
78
79 tislelizumab tislelizumab
80
81 ABRAXANE REVLIMID VIDAZA
82
83 % 2,
84
85 (i)(ii)(iii)
86
87
88
89 (General Data Protection Regulation)(EU) 2016/679 10,000,0002% 20,000,000 4% (HGR)
90
91
92 (Export Administration Regulations))
93
94 (BEPS)
95
96
97 37 (i) (ii) (i)(ii) (iii) (iv)
98 10% 50% % 10%
99 5% (i)(ii) (iii)(iv)
100 25% % 10%
101
102 K
103
104
105 ,113, ,894,893 46,145, ,279,37023,021,
106
107
108
109
110
111 DTCDTC DTC
112 %
113 (1)75%(2)50% (Internal Revenue Service)
114 (CFC) Subpart F(Subpart F income) 50%50% 10%10%1986 (Internal Revenue Code of 1986)
115 , ,885 13,035 8,816 1, ,959 67,335 13,035 8,816 1, , ,220 13,035 8,816 1, , ,515 18,546 57, ,163 91, ,829 18,546 57, ,217 93, ,033 (1) 11,909 46, ,592 50, ,906 BeiGene, Ltd. 18,278 57, ,217 93, ,769 (%) 100% 100% 100% 98% 86% (%) -142% -648% % -39% -340% (%) (1) -91% -532% % -21% -296% ,898 17,869 87, , ,713 30,497 82, , ,914 1,068,509 33,817 71, , ,509 1,697,390 53, , ,813 1,046,479 2,249,684 27,853 42,445 52, , ,037 78, ,084 14,422 14,445 (53,041) (101,765) 352, ,231 1,753,647 (1) (2) 10-K
116 (1) zanubrutinib(bgb-3111) (BTK)(2) tislelizumab (BGB-A317) 1(PD-1)(3) pamiparib (BGB-290) 1 (PARP1) PARP (R/R)(MCL) R/RR/R(CLL/SLL)zanubrutinibR/R (chl) tislelizumab
117 Ambrx Inc.Ambrx Inc Ambrx Inc (FDA)(BTK) Zanubrutinib(Breakthrough Therapy designation) MCL BTKzanubrutinibZanubrutinibBTK 2 3 BTK zanubrutinib
118 Tisleizumab PD-1 PD-L1 tislelizumab
119 Mirati Therapeutics, Inc. (Mirati) Zymeworks Inc. (Zymeworks) % 4. Baker Bros. Advisors LP Hillhouse Capital Management, Ltd. (5)
120 tislelizumab 2017 pamiparib lifirafenib 2013 ABRAXANE REVLIMID VIDAZA
121 zanubrutinibbtk tislelizumabpd-1 pamiparibparp1 PARP2 lifirafenibbraf BGB-A333PD-L1 BGB-A425TIM-3 sitravatinibmirati Therapeutics, Inc. ZW25 ZW49Zymeworks Inc.HER
122
123 18A.08(3) ABRAXANE REVLIMID VIDAZA
124 % 130,885 24, , % 67, ,959 (146,624) (69)% 198, ,387 (40,167) (17)% (28,705) (4,974) (23,731) 477% (679,005) (269,018) (409,987) 152% (195,385) (62,602) (132,783) 212% (894) (250) (644) 258% (903,989) (336,844) (567,145) 168% (705,769) (98,457) (607,312) 617% 13,947 (4,108) 18,055 1,993 11,501 (9,508) (83)% (689,829) (91,064) (598,765) 658% 15,796 (2,235) 18,031 (674,033) (93,299) (580,734) 622% (264) (194) (70) 36% (673,769) (93,105) (580,664) 624%
125 % 130,885 24, , % 211,391 (211,391) (100)% 56,776 56,776 10,559 2,568 7, % 67, ,959 (146,624) (69)% 198, ,387 (40,167) (17)% ABRAXANE REVLIMID VIDAZA VIDAZA
126 % % 291, , , % 89,000 89,000 % 55,600 9,244 46, % 243, , ,940 90% 679, , , % zanubrutinibtislelizumabpamiparib sitravatinib lifirafenib Miratisitravatinib 10ZW25 Zymeworks, Inc.60 PARP
127 %
128 % ABRAXANE REVLIMID VIDAZA %
129 ,673 21,156 14,588 9,894 3,096 1,557 5,585 3,016 81,942 35, % % ,191 65, ,376 3, , , ,283 69,
130 ,887 17,051 34,588 18,721 10,433 2,350 8,030 5,088 4,749 3,997 6,727 2, ,414 49, % (i) (ii)(iii) (Merck KGaA, Darmstadt Germany) ABRAXANE REVLIMID VIDAZA
131 ,602 87,514 (547,717) 12,752 (637,613) (356,319) 1,690, ,356 (4,096) 5, , , , ,
132 Mirati Zymeworks
133 Mirati Zymeworks Celgene Switzerland
134 zanubrutinibtislelizumab pamiparib
135 ,809 10,752 17,777 5, ,399 8, ,960 36,572 9,747 9,747 45,910 45, ,865 75,136 17, ,135 36,
136 % % , , , ,
137
138 (i)(ii)(iii) (iv)(v) 606 ABRAXANE REVLIMID VIDAZA
139
140 (i)(ii) (1)(2) (3) (4) (5)
141
142
143 % ~ 3.1% 2.2% ~ 2.6% 2.2 ~ ~ % ~ 64% 99% ~ 100% 0% 0%
144 ,384 30,610 32,743 12,253 87,127 42,
145 %
146 % 6.5%
147 % 11.3% , ,
148
149 Donald W. Glazer 74 Michael Goller 44 Ranjeev Krishana 45 Thomas Malley BioDuro, LLCPharmaceutical Product Development Inc Galenea Corp Telephia, Inc.2007(The Nielsen Company) Genta Incorporated (McKinsey & Company)
150 Howard Hughes Medical Institute George L. MacGregor 2004Joyant Pharmaceuticals, Inc Asia Pacific Telecom (Telstra International Group)TelstraAutohome Telstra Corporation Limited GL Capital Group CN
151 Donald W. Glazer Glazer GMO Trust2005GMO TrustGlazer Provant, Inc GlazerMugar/Glazer Holdings WHDH-TV, Inc.1997GlazerGoodwin Procter LLP Ropes & Gray LLP Ropes & Gray Provant, Inc.Glazer Environics Inc.Kronos IncorporatedReflective Technologies, Inc. Teleco Oilfield Services Inc. Glazer GlazerGlazer and FitzGibbon on Legal Opinions Massachusetts Corporation Law& Practice Glazer Michael Goller GollerBaker Bros. Advisors LP 2005Baker Bros.Goller JPMorgan Partners, LLC Goller(Merrill Lynch and Co.)Goller GollerDBV Technologies SALevo Therapeutics, Inc. Goller Ranjeev Krishana Krishana2011 Baker Bros. Advisors LPBaker Bros.Krishana (Pfizer, Inc.) Krishana KrishanaKrishanaAccenture plc Krishana Krishana
152 Thomas Malley Malley Mossrock Capital, LLC MalleyJanus Mutual Funds MalleyJanus Global Life Sciences FundJanus MalleyJanusMalley MalleyKura Oncology, Inc. 2015Kiniksa Pharmaceuticals2016 OvaScience Inc Millendo Therapeutics, Inc Synageva BioPharma Corp Puma Biotechnology, Inc Cougar Biotechnology, Inc Malley , (Tricon Global Restaurants International)(Procter & Gamble) Peet s Coffee China (Hillhouse Capital)
153 (Pfizer Essential Health) (RDPAC) (NDPE) Leerink Partners LLCSVB Leerink LLC A.G. Edwards Inc JMP Securities Prudential Securities (Abbott Laboratories)
154 Acerta PharmaBTKacalabrutinib Genentech, Inc. venetoclax obinutuzumab (B)(1)
155 BGNE
156 tislelizumabpamiparib % 66.0%0.8% pamiparib % 10.3%0.4% pamiparib % 62% 15% 19% %
157
158 (%) Zanubrutinib 282, % 46, ,338 Tislelizumab 282, % 65, ,212 Pamiparib 86, % 13,442 73,528 (a) 652, % 125, ,078 (b) 130, % 58,259 72,197 (c) 86, % 32,030 54, , % 215, ,216 (a) (b) (c)
159 ,
160 Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley
161 Ranjeev Krishana
162 50,000 22,500 10,000 17,500 7,500 12,500 5, , , ,000,
163 %
164 ,000 65% (i)(ii)(iii)(iv) (i) (ii)12(iii) (iv)20,000(v) ,
165
166 XV (a)xv7 8 (b) 352(c) (1) 34,110,070 (2) 4.40% 10,000,000 (3) 1.29% 102,188 (4) 0.01% 7,952,787 (5) 1.03% 29,439,115 (6) 3.80% 510,941 (7) 0.07% 15,994,751 (8) 2.06% 224,372 (9) 0.03% 5,000,000 (10) 0.65% 657,346 (11) 0.08% Donald W. Glazer 4,518,952 (12) 0.58% 38,160 (13) 0.005% Michael Goller 226,724 (14) 0.03% Ranjeev Krishana 226,724 (15) 0.03% Thomas Malley 1,139,472 (16) 0.15% 63,290 (17) 0.01% 226,724 (18) 0.03%
167 (1) ,576,070 (2) (1)16,270,707(2)16,689,898 (3)1,149,465 (3) Roth IRA PENSCO (4) The John Oyler Legacy Trust (5) (6) Oyler Investment LLC Oyler Investment LLC 99% (7) The Oyler Family Legacy Trust (8) (1)7,306,967(2)8,286,143 (3)401,641 (9) (10) Wang Investment LLCWang Investment LLC99% (11) (1)648,056 (2)9,290 (12) (1) Glazer4,292,228(2)GlazerGlazer 217,434(3) Glazer9,
168 (13) GlazerGlazer (14) (1)GollerGoller217,434 (2) Goller9,290 (15) (1)KrishanaKrishana217,434 (2) Krishana9,290 (16) (1) Malley390,000(2)MalleyMalley 740,182(3)Malley9,290 (17) 63,290 (18) (1)217,434 (2)9, (a)xv7 8 (b)352(c)
169 XV (1) Julian C. Baker (2) 161,880, % Felix J. Baker (2) 161,880, % Baker Bros. Advisors (GP) LLC. (2) 161,745, % Baker Bros. Advisors LP (2) 161,745, % Baker Brothers Life Sciences Capital, L.P. (2) 145,425, % Hillhouse Capital Management Ltd. (3) 13,445, % Gaoling Fund, L.P. (3) 58,995, % Hillhouse Capital Advisors, Ltd (3) 63,117, % Fidelity Management & Research Company (4) 76,202, % FMR Co., Inc. (4) 71,180, % FMR LLC (4) 78,936, % Fidelity Mt. Vernon Street Trusts (4) 38,393, %
170 (1) ,576,070 (2) Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLCBaker Bros. Advisors (GP) LLC Baker Bros. Advisors LPBaker Bros. Advisors LP 667, L.P. Baker Brothers Life Sciences, L.P.Julian C. BakerFelix J. Baker Baker Bros. Advisors (GP) LLC Baker Bros. Advisors LP 667, L.P. 16,319,660 Baker Brothers Life Sciences, L.P. 145,425,622 Julian C. Baker Felix J. Baker FBB3 LLC92,32643,069 (3) (i)58,995,800 Gaoling Fund, L.P. (ii) 4,121,589 YHG Investment, L.P. (iii)13,445,978hillhouse BGN Holdings Limited Hillhouse Capital Adrisors, Ltd.YHG Investment, L.P.Gaoling Fund, L.P.Hillhouse Capital Management, Ltd. Hillhouse Fund II, L.P.Hillhouse Fund II, L.P.Hillhouse BGN Holdings Limited Hillhouse Capital Adrisors, Ltd.Gaoling Fund, L.P.58,995,800 YHG Investment, L.P.4,121,589Hillhouse Capital Management, Ltd. Hillhouse BGN Holdings Limited13,445,978Hillhouse Fund II, L.P.Hillhouse BGN Holdings Limited13,445,978 (4) JohnsonAbigail P. JohnsonFMR LLC B FMR LLC 49JohnsonB B B Fidelity Management & Research Company 76,202,40869,720,508 FMR Co., Inc12,048,80571,180,714 Fidelity Management & Research (Hong Kong) Limited4,694,900 Fidelity Mt. Vernon Street Trust38,393,094Fidelity Mt. Vernon Street Trust 274,45336,118,641 FMR Co., Inc.71,180,714FMR Co., Inc.4,617,10066,563, XV
171 ,550, ,359, ,235 88, , , , ,000 Thomas Malley , , ,900, ,000 4,445, ,630,682 2,485, ,769 11,894, ,550,936 2,940, ,769 18,359,
172 % % %
173 10 (i) 1/13(ii) 1/
174 ,251, ,442, (1) (2) (3) ,047,500 2,047, (3) , , (3) , , (3) ,310,088 1,310, (3) ,613,430 1,613, (3) , , (3) , , (4) , , (5) , , (5) ,442 17,442 Donald W. Glazer (4) , , (5) ,442 17,442 Michael Goller (4) , , (5) ,442 17,442 Ranjeev Krishana (4) , , (5) ,442 17,
175 (1) (2) Thomas Malley (5) , , (5) ,442 17, (4) ,290 63, (4) , , (5) ,442 17, (3) ,752,500 1,752, (3) ,250,000 1,250, (3) , , (3) ,367,500 39,000 1,328, (3) , , (3) , , (6) , ,
176 (1) (2) (3) ,376,000 1,831, , (3) ,765,800 1,015, ,631 9,377, (3) ,657, , ,830 1,305, (6) ,496, ,826 55,192 2,966, (3) ,094 87, , (3) ,000 39, , (3) ,599, , , (3) ,259 14,885 26, (3) ,813 16, , (3) ,325 13,000 74, (3) ,998 32, , (6) ,680 2,340 9, (3) ,999 89, (3) ,917 2,080 70, (3) , , , (3) , , (3) ,991 68,796 91, (3) , , (3) ,984 95, , (3) ,505 41, , (3) ,990 15, (3) , , , (3) , , (3) , , , (3) , , , , (3) , , , , (3) ,990 13,741 41, (3) , , , (3) ,987 62, , (6) , , , , (3) ,982 46, , (3) ,047 51, ,
177 (1) (2) (3) ,231,971 94,991 89,999 1,046, (3) ,994 34, , , (3) ,990 6,916 9, (3) , , , (3) ,500 18,408 92, (3) ,500, , , (3) ,974 32, , (3) ,977 2, , (3) ,976 47, , (3) , , , (3) ,995 32, , (3) ,997 37, , (6) , ,995 32, , (3) ,988 58, , (3) , , , (3) , , (3) ,194, , , (3) ,990 57, , (3) , , (3) ,409, ,156 1,136, (6) ,890 31,291 11, , (3) ,976 54, , (3) , , , , (3) ,987 48,594 96, (3) ,977 40,560 11, , (3) ,378 86, , (6) ,792,492 58,890 25,064 1,708, (3) ,980 14, , (3) ,265, , ,538 2,700, (6) ,981, , ,475 8,266, (3) , , (3) , , (3) ,996 99, (3) ,744, , ,832 6,401, (3) ,600 29,848 8, , (3) , , (3) ,973 3, , (3) ,994 32, , (6) ,337, ,248 67,327 1,126, (3) ,999 2,990 9, (3) , , (6) ,060,033 77,571 11, , (3) ,300,000 1,300,
178 (1) (2) (6) ,992 19, , (3) ,994 19, (3) , , , (3) ,990 54, (3) , , (3) , , (3) ,973 89, , (3) , , (3) , , (3) , , (6) ,148,888 67,288 39,468 1,042, (3) ,973 74, , (3) , , (3) , , (3) ,990 54, (3) ,976 58, , (3) ,974 74, , (3) , , , , (3) , , , (3) ,947 26, , (3) , , (3) , , (3) , , (3) ,604 32, (3) , , (3) ,500 56, (3) ,222,013 44,486 3,177, (3) ,966 80, (3) , , (3) , , (3) ,827 43, (3) , ,501 90,251,295 9,308,481 10,900,579 6,216,330 82,442,
179 (1) 13 (2) 13 (3) 25%75% 3625% (4) (5) (6) 20%80% 4820% % % %10%25,
180 % ,000,
181 , (1) (2) ,404 79,404 79,404 79,404 (1) 13 (2) 25%75% 3625% (c)(4) ,000,
182 % 10 (i) 1/13(ii) 1/
183 Thomas Malley Thomas Malley
184
185 A C.3.3 C B
186 A B.8 Scott A. Samuels Scott A. Samuels
187 Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley
188 A.4.1 A
189
190 10-K Thomas MalleyThomas Malley3.10(2) (2)
191 Ranjeev Krishana ,000,00026,000,
192 Donald W. GlazerMichael GollerDonald W. Glazer
193 (Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands(a)(b) a-8(b)(2) (c) (d)(e) (f)(i)(ii) (g) D
194 /10 2/2 7/10 0/2 9/10 6/6 6/7 1/2 Donald W. Glazer 10/10 2/2 2/2 Michael Goller 10/10 2/2 2/2 Ranjeev Krishana 10/10 7/7 2/2 Thomas Malley 10/10 8/8 2/2 6/6 2/2 9/10 8/8 7/7 0/2 A
195 Donald W. GlazerMichael GollerRanjeev KrishanaThomas Malley ,396 1, ,580 1, Q
196 A A Committee of Sponsoring Organizations of the Treadway Commission
197
198
199 (i)(ii) Vistra Corporate Services (HK) Limited Scott A. Samuels
200 (Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands (Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands[ ] (
201 (1) (2)
202 o o
203 o o o o o
204
205 ISO14001(EHS) EHSEHS EHSEHSEHS EHS 1. LED
206 2. 14,600 17, ,
207 , , , , , ,
208 2015 (IPCC)2006 IPCC , , , , , , (GB/T )
209
210
211 EHSEHS EHS
212 EHS EHS (elms) (QA)
213 EHS
214 zanubrutinib(bgb-3111) (BTK)tislelizumab (BGB-A317) 1(PD-1)pamiparib (BGB-290) 1 (PARP1) PARP2 lifirafenib (BGB-283)RAF BGB-A333PD-L1BGB-A425 TIM-3 sitravatinibmirati Therapeutics, Inc.(Mirati) ZW25 ZW49Zymeworks Inc. ZymeworksHER ABRAXANE REVLIMID VIDAZA avadomide(cc-122)cereblon tislelizumab (GMP) ICH Q
215 (BeiGene Quality Manual) QA QA QA 2018 (FTO)
216 (PCT) 2018 (CRO) CRO
217 (HGR)HGR
218 elms
219 (T&E) REVLIMID NDMM RRMM NDMM RRMMNDMM
220
221 , , , ,068, , ,056 29, , ,242 10, ,942 35,623 1,943, , , ,061 62, ,058 12, ,172 7, ,542 7, ,668 42, , ,982 2,249,684 1,046, ,283 69, ,414 49,598 18,140 12, ,888 9, ,727 9, , ,
222 ,785 9, , ,271 9,842 24, , ,931 31, , , , , ,500,000, ,263, ,072, ,744,814 1,000,747 1,526 (480) (1,007,215) (330,517) 1,739, ,809 14,445 14,422 1,753, ,231 2,249,684 1,046,
223 ,885 24, , , , ,387 (28,705) (4,974) (679,005) (269,018) (195,385) (62,602) (894) (250) (903,989) (336,844) (705,769) (98,457) 13,947 (4,108) 1,993 11, (689,829) (91,064) 13 15,796 (2,235) (674,033) (93,299) (264) (194) (673,769) (93,105) 20 (0.93) (0.17) ,753, ,185,460 (12.15) (2.23) 55,442,601 41,783,
224 (674,033) (93,299) (478) 851 2,133 (296) (672,378) (92,744) (352) (105) (672,026) (92,639)
225 (674,033) (93,299) 10,388 4, ,127 42, , ,820 7,035 (21,949) (5,845) (1,948) (44) (8,034) (11,628) (29,428) 7,695 (5,312) (10,930) (46,302) (28,880) (40,228) (29,701) 23,470 55,298 50,543 24,978 (3,355) 7,426 (9,059) 37,041 16,962 31,395 (547,717) 12,752 (70,283) (46,374) (553) 4 (38,298) (12,354) 4 19,916 (2,635,686) (741,296) 2,177, ,789 1 (70,000) (637,613) (356,319)
226 , , (414) (674) , (5,659) , ,315 (8,736) 2,470 (2,470) 14, ,757 29,662 4,627 1,690, ,356 (4,096) 5, , , ,602 87, , , , ,602 14,544 13,232 12,361 29,286 2,209 1,260 23,606 22,105 2,215 19,000 2,
227 ,833, ,213 (946) (237,412) 352, ,907 36,851, , , ,517 32,746, , , ,928 23,606 23,606 23, ,527 14,527 42,863 42,863 42, ,571 5,852,984 4,627 4,627 4, (93,105) (93,105) (194) (93,299) ,072, ,000,747 (480) (330,517) 669,809 14, , (2,929) (2,666) 375 (2,291) ,072, ,000,747 (217) (333,446) 667,143 14, , ,970, , , ,587 65,600, , , ,709 1,299,186 87,127 87,127 87,127 14,321, ,661 29,662 29,662 1,743 1,743 (88) 1,655 (673,769) (673,769) (264) (674,033) ,263, ,744,814 1,526 (1,007,215) 1,739,202 14,445 1,753,
228 Celgene Switzerland LLC Celgene Switzerland , BeiGene % BeiGene AUS Pty Ltd. BeiGene Australia % ,711, % ,940,244,615 95% * ,000,000 95% ,000, %
229 1. BeiGene(Hong Kong) Co., Limited % ,000, % BeiGene Ireland Limited BeiGene Ireland % ,800, % ,000, % * ,344,310 95% ,000, % BeiGene Switzerland GmbH BeiGene Switzerland , % BeiGene UK, Ltd. BeiGene UK % BeiGene USA, Inc. BeiGene USA % *
230
231
232 (i)(ii)
233
234 (i)(ii)(iii) (iv) (i) (ii)
235 ABRAXANE REVLIMID VIDAZA CC
236 (1)(2)(3)
237 ,068, ,810 1,228, ,327 17,663 18,924 44, ,
238 (i)(ii)(iii) (iv)(v)
239 2. ABRAXANE REVLIMID VIDAZA
240
241 2. (i)(ii) (i) (ii)(iii) (iv) (v)
242
243 2. (a) (b)(c) 75% (d)90%
244
245
246 %
247 ,937239, ,068,509597,
248
249 %6.5%
250 EITF S
251 , , , , (1)(2)
252 ,307 16,307 42,915 (28,588) 14,327 31,959 (9,990) 21,969 (480) 263 (217) (330,517) 16,307 (19,236) (333,446) 14, ,
253 ,00030,000 45,
254
255 3. (1)1 PD-1 tislelizumab(2) pamiparib lifirafenib ,391 56,776 10,559 2,568 67, ,959 Celgene Switzerland Celgene Switzerland PD-1tislelizumab PD Celgene SwitzerlandPD-1A&R PD-1 A&R PD-1263,000 92, , Celgene Switzerland 12 13,000 Celgene Holdings East Corporation A&R PD
256 3. Celgene Switzerland tislelizumaba&r PD-1 tislelizumab tislelizumab tislelizumab 606(a) tislelizumab(b)tislelizumab 250, , ,776 16, , ,391 1,
257 lifirafenib lifirafeniblifirafenib lifirafenib Lifirafenib RAF lifirafenib lifirafenib 2013pamiparib pamiparib pamiparib pamiparib 10, pamiparib , pamiparib3 1, pamiparib19,
258 lifirafenib pamiparib Zymeworks, Inc ZymeworksZymeworks ZW25(ADC) ZW49 Zymeworks ZymeworksAzymetic EFECT Zymeworks ZW25 ZW49HER2 Zymeworks ZW25 ZW49 ZW49 ZW25Zymeworks40, ,000Zymeworks ZW25 ZW49 Azymetric EFECTZymeworks20, ,000 Zymeworks 60,
259 Celgene Holdings East Corporation Celgene Logistics Sàrl Celgene Logistics ABRAXANE REVLIMID VIDAZA CC-122 A&R PD Celgene Switzerland Celgene Switzerland32,746,416150,
260 4. 28,1384,53223, ,532 23,606 28,138 24, ,500 1,069 33,739 (5,710) (5,710) ,
261 4. 24,448 (4,532) 19,916 (23,606) ,654 38, ,783 15,874 (11,221) ,
262 , ,066,770 1, ,068,509 1,066,770 1, ,068, , ,327 17, ,663 18,924 18, , ,
263 ,056 29,428 41,056 29, ,056 18, ,521 41,056 29, ,
264 ,24210, % 1 5% ,8302, % 100% 95% % 5% ,
265 ,636 15,596 18,048 15,298 15,857 16,048 15,737 2,216 1,597 1,229 1,244 1, ,296 50,070 (19,722) (13,627) 99,487 26, ,061 62, ,48726, ,0004, ,701 12,633 (643) (168) 45,058 12, , , , , , ,
266 ,500 (1,000) 6,500 7,500 (250) 7, (144) 672 8,316 (1,144) 7,172 7,500 (250) 7,250 ABRAXANE REVLIMID VIDAZA CC , ,
267 % % 25% % BeiGene AUS Pty Ltd. 30%BeiGene AUS Pty Ltd. BeiGene USA % 35% BeiGene USA
268 13. BeiGene Switzerland10.5% BeiGene Switzerland (130,552) (59,590) 15,036 6,928 (574,313) (38,402) (689,829) (91,064) ,890 2,477 (377) 5,695 6,513 8,172 (2,682) 115 (19,627) (6,052) (22,309) (5,937) (15,796) 2,
269 (689,829) (91,064) 25% 25% (172,457) (22,766) 134,673 23,275 4,471 1,608 1,538 2,642 (29,438) 34,009 30,356 (12,659) (5,431) (5,371) 1,989 (15,796) 2, % -2.5% ,193 7,756 61,266 29,801 8,642 4,639 13,608 2, , ,348 44,645 (242,945) (36,600) 18,403 8,045 (370) (370) 18,403 7,
270 ,00930, , ,769209, , , ,780 22,68814, (44) (91) 1, , ,
271 , ,673 21,156 14,588 9,894 3,096 1,557 5,585 3,016 81,942 35,
272 ,981 12,867 (1) 25,193 28,588 14,671 1,823 1,460 53,668 42,915 (1) ,887 17,051 34,588 18,721 10,433 2,350 8,030 5,088 4,749 3,997 6,727 2, ,414 49, ,851 31,804 1, ,931 31,
273 ,191 65, ,376 3, , , ,283 69, %17, , , , , , % , ,2531,
274 ,727 9,222 9,222 4,213 36,572 49,512 18, %
275 % ,894 7,6493, , , , ,
276 18. ABRAXANE REVLIMID VIDAZA ,046 28,428 (7,161) (4,000) 130,885 24, ,000 (3) ,997 7,161 (6,409) ,
277 ,705 4,974 9,000 4, , ,018 8,930 3, ,396 1, ,115 65,608 87,127 42,863 12,409 4, , ,086 (1,948) (44) 4,184 (232) (23,401) (4,188) ,08580,
278 (673,769) (93,105) 720,753, ,185,460 (0.93) (0.17) ,029, ,144, (i)5% (ii) ,603, ,553,
279 ,889, ,000, (c)(4)5635(c)(4) ,500, ,855,315 7,355, % 10%
280 ,079, ,085, (5,887,193) ,723 (6,275,115) ,002, ,387, (13,841,036) ,687 (6,467,099) ,082, , ,829, , ,857, , ,027,926154, ,642 20,
281 ~ ~ % ~ 3.1% 2.2% ~ 2.6% 2.2 ~ ~ % ~ 64% 99% ~ 100% 0% 0%
282 ,075, , (268,750) 2.04 (300,000) , (387,500) 2.12 (118,750) , ,
283 ,469, ,469,442 14,079, (689,130) 8.33 (757,458) ,102, ,692, , ,384 30,610 32,743 12,253 87,127 42,
284 ,600,000 85,800, ,00012,870, , ,781,25075,156, ,00011,050, ,7506,093, , ,465,00032,045, ,7504,806, , S ,425,750 96,534,750495,050 6,435, , S ,600, ,
FCIS FCS Scott A. Samuels Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley Thomas Malley Ranjeev Krishana Donald W. Glazer Michael Golle
2 4 24 38 39 40 42 43 45 87 90 1 B E I G E N E, L T D. 2 0 1 8 FCIS FCS Scott A. Samuels Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley Thomas Malley Ranjeev Krishana Donald W. Glazer Michael
BeiGene, Ltd XIVA
BeiGene, Ltd. 06160 2018 12 31 2018 12 31 13.09 571 XIVA 2018 12 31 2018 12 31 2018 12 31 2018 12 31 2019 1 2019 2 27 1 2019 3 312018 12 31 1995 10-Q 2019 2 28 Donald W. Glazer Michael Goller Ranjeev Krishana
BeiGene, Ltd XIVA BeiGene, Ltd. BeiGene
BeiGene, Ltd. 06160 2018 9 30 13.09 571 XIVA BeiGene, Ltd.BeiGene 2018 9 30 2018 9 30 2018 2018 1 2018 11 7 1 1995 (Private Securities Litigation Reform Act of 1995) 10-Q BeiGene, Ltd. 2018 11 8 Donald
t03phip
[ ] [ ] [ ] [ ] [ ] [ ] [ ] 1 6.5 2017 12,090 2030 24,570 2017 1,106 9.1% 139 2030 4,068 16.6% 2013 2030 7.3% 7.6% 7.5% 8.1% 72.9 79.2 83.2 93.7 9.1% 110.6 10.1% 128.3 11.0% 147.6 11.8% 166.8 13.1% 12.6%
t07aplp
Hansoh Pharmaceutical Group Company Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) 1933 (k) [Logo] Hansoh Pharmaceutical Group Company Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] 0.00001 [
(RICI Heath) AR chi.indb
RICI HEALTHCARE HOLDINGS LIMITED : 1526 2016 2 6 8 9 10 12 16 28 48 67 81 88 2017 2017 6 2 2016 6 23 2015 5 20 2014 7 11 2013 11 6 500 2 2014 7 11 (i)(ii) 2015 2 16 2015 6 29 3 2016 10 6 2016 10 6 2008
2 4 5 9 14 21 24 35 39 41 42 43 44 46
2014 2 4 5 9 14 21 24 35 39 41 42 43 44 46 2 3 88 35 Codan Trust Company (Cayman) Limited 2901 8 40 183 17 1712-1716 www.xiabu.com 520 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111
( 於中華人民共和國註冊成立的股份有限公司 ) 股 份代號 3606 (A joint stock limited company incorporated in the People's Republic of China with limited liability) Stock Code: 3606 2016 2016 中期報告 Interim Report 2016 中期報告 Interim
untitled
1949 10 2016500 119 02328 68.98% 75.0% 80.0% 95.45% 100% 100% 100% 2 3 25 42 43 81 2016 6 30 2015 12 31 (%) 902,276 843,468 7.0 738,847 686,273 7.7 163,429 157,195 4.0 (1) 2.85 2.74 4.2 6 30 6 2016 2015
2 3 4 5 17 22 23 24 26 27 28 1 2017 7 31 2017 7 31 2017 6 29 2017 6 29 2017 6 29 2017 6 29 2017 6 29 2017 6 29 2017 6 29 2017 6 29 2017 2 26 23 2305-06 600 S2 11 Cricket Square, Hutchins Drive PO Box 2681
China Dredging Environment Protection Holdings Limited 871 2015 2 3 5 6 13 20 22 23 25 26 27 Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands 1 168 200 36 19 Codan Trust
i
01610 (I) (II) (III) 5 23 24 25 41 8 301150 51 183 2248 ... 1... 5... 24... 25... 42... 49... 50 i 1 16 9 2 571 3 % 4 01610 WOLHARDT Julian Juul P.O. Box 31119 Grand Pavilion, Hibiscus Way 802 West Bay
目 錄 頁 次 釋 義......................................................... 1 董 事 會 函 件..................................................... 3 言.............
此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問 應諮詢 閣下的股票經紀 其他持牌證 券商 銀行經理 律師 專業會計師或其他專業顧問 閣下如已售出或轉讓名下所有金嗓子控股集團有限公司的股份 應立即將本通函連同隨附的代 表委任表格送交買主或承讓人 或經手買賣的銀行 股票經紀或其他代理人 以便轉交買主或 承讓人 香 交易及結算所有限公司及香 聯合交易所有限公司對本通函的內容概不負責 對其準確性
untitled
2 3 6 13 17 25 31 44 48 49 51 52 54 116 1 Cricket Square, Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands B 9-A 1 36 SMP Partners (Cayman) Limited 3rd Floor, Royal Bank House 24 Shedden
: O16
: 1198 2O16 2 3 4 6 19 22 31 36 37 38 40 41 43 104 01 Donald H. Straszheim Donald H. Straszheim Donald H. Straszheim Donald H. Straszheim Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor,
China Dredging Environment Protection Holdings Limited 2013 02 03 05 07 08 13 25 31 41 51 53 Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands 1 168 200 36 19 Codan Trust
書冊C_ indb
38D 1933 0440 36.89 32,533,8312.00 8 1 8 10 (i)(ii) (iii) (i)(ii) (iii) i 6D 6D 6D 6D 6D 708 707 6D 6D ii Capital Markets and Services Act 2007 CMSA CMSA 229(1)(b) 230(1)(b) 6 7 iii CMSA 5 Securities Act
2018 Hope Education Group Co., Ltd
2018 Hope Education Group Co., Ltd. 2018 7 14 2018 8 3 1 2018 Hope Education Group Co., Ltd. 2018 7 14 2018 8 3 2 2018 Hope Education Group Co., Ltd. 2018 7 14 2018 8 3 1 Hope Education Group Co., Ltd.
2 4 6 18 26 34 48 50 51 52 53 55 56 110 2013 139.8 8.2 IPO 0.4 19.4 0.04 177 2 3 2013 P.O. Box 613 GT 4th Floor Harbour Centre George Town Grand Cayman KY1-1107 Cayman Islands 599 B 23 361016 183 54 1
02 04 05 07 15 17 18 19 20 41 43 02 GBS, OBE, JP GBS, OBE, JP Conyers Dill & Pearman GBS, OBE, JP GBS, OBE, JP Butterfield Fund Services (Cayman) Limited Butterfield House 68 Fort Street P.O. Box 705,
ASCENT INTERNATIONAL HOLDINGS LIMITED 264 8510 15 18 48 ................................................................ 1........................................................... 3............................................
Hospital Corporation of China Limited [ ] [] [][] [] [][] [] [][][] [] [][] [] [ ] [] [] [] C [] [][][][] [] [][][][][] [][][]1% %0.
![Hospital Corporation of China Limited [ ] [] [][] [] [][] [] [][][] [] [][] [] [ ] [] [] [] C [] [][][][] [] [][][][][] [][][]1% %0.](/thumbs/50/26829738.jpg "Hospital Corporation of China Limited [ ] [] [][] [] [][] [] [][][] [] [][] [] [ ] [] [] [] C [] [][][][] [] [][][][][] [][][]1% %0.")
Hospital Corporation of China Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) 1933 (j) (k) Hospital Corporation of China Limited [ ] [] [][] [] [][] [] [][][] [] [][] [] 0.001 [ ] [] [] [] 32 342C [] [][][][]
untitled
China Suntien Green Energy Corporation Limited* 00956 Asian Capital (Corporate Finance) Limited 5 2122 23 2450 2015 12 285 20152015 11 11 H 2015 12 8 H * 2015 12 11 ........................................................
2 5 14 15 16 18 20 22 51 1 2018 MH, FCCA, FCPA (PRACTISING), ACA, CTA (HK), FHKIoD UFJ Conyers Dill & Pearman, Cayman 2018 2 18 29 A Century Yard Cricket Square Hutchins Drive P.O. Box 2681GT George Town
1638
1638 1999 2009 12 9 1638.HK 2 4 8 12 24 40 45 48 56 69 71 73 74 75 76 77 138 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman, KY1-1111 Cayman Islands 3306 2 8 20 2001 Butterfield Fulcrum Group
目錄 財務摘要 2 合併股東權益變動表 53 董事長報告 3 合併現金流量表 55 管理層討論與分析 5 資產負債表 57 董事 監事及高級管理層 11 利潤表 59 企業管治報告 19 股東權益變動表 60 董事會報告 32 現金流量表 62 監事會報告 46 財務報表附註 64 審計報告 48 詞彙表 168 合併資產負債表 50 公司基本資料 170 合併利潤表 52 註 1. 2. 本年度報告中的財務數據根據中國會計準則編製
於開曼群島註冊成立的有限公司 股份代號 3738 Vobile Group Limited 阜博集團有限公司 Vobile Group Limited 阜博集團有限公司 Vobile Group Limited 阜博集團有限公司 (Incorporated in the Cayman Islands
於開曼群島註冊成立的有限公司 股份代號 3738 Vobile Group Limited Vobile Group Limited Vobile Group Limited (Incorporated in the Cayman Islands with limited liability) Stock Code: 3738 2018 2018 中期報告 INTERIM REPORT INTERIM
314390 chi.indb
CHINA MINSHENG BANKING CORP., LTD. 01988 2011 12 31 (www.hkexnews.hk) (www.cmbc.com.cn) H 2012 3 22 5 222011 AH 103.0 2011 2012 3 22 3 4 7 45 56 68 97 98 108 112 114 116 221 222 1 2012 3 22 181815 3 3
Shineroad International Holdings Limited 1587 6 17 18 19 20 35 291103 06 43 44 (www.hkexnews.hk) (www.shineroad.com) 48 18322 ...................................................................... 1...............................................................
Colour Life Services Group Co., Limited 2014 2 3 4 8 8 16 26 29 31 32 33 35 36 37 2 Cricket Square, Hutchins Drive PO Box 2681, Grand Cayman KY1-1111, Cayman Islands 12 16 16 18 1 1202 03 1778 www.colourlife.hk
/ 2015 CONSOLIDATED STATEMENT OF PROFIT For the six months ended 30 December
(於開曼群島註冊成立的有限公司) 股份代號 : 3313 (incorporated in the Cayman Islands with limited liability) STOCK CODE: 3313 2015 年度報告 2015 A N N UA L R E P O R T / 2015 CONSOLIDATED STATEMENT OF PROFIT For the six months
(i)(ii) (iii) (iv)
* 於開曼群島註冊成立的有限公司 股份代號 1548 * 2015 年度報告 * 僅供識別 (i)(ii) (iii) (iv) 2 3 5 6 7 10 20 26 43 57 59 60 61 63 65 67 1 (i)(ii) (iii) (iv) 76.92.56.01.388.7% 2.9% 6.9%1.5% 57.2% 25.0% 12.9% 1.5% 3.4% 100 43.617.012.36.63.7
t08phip
Zhou Hei Ya International Holdings Company Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) 1933 Zhou Hei Ya International Holdings Company Limited [ ] [ ] [ ] [ ][ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ][ ]
409918 (Minshing A share).indb
600016 2011 2012 3 22 181815 33 2011 2 4 6 8 12 46 54 64 90 91 99 102 104 107 110 111 113 230 236 237 240 2011 1 2 2011 279.2058.81% 1.40%0.3123.95%5.66 0.63% 0.06 357.29% 86.842.23%0.35 20062009 2010
YESTAR INTERNATIONAL HOLDINGS COMPANY LIMITED (Incorporated in the Cayman Islands with limited liability) () Stock Code : 2393 Annual Report 2015 2 4 7 10 26 30 41 53 55 56 57 59 60 62 128 Sutikno Liky
- 2017
- 2017 4 8 18 22 26 32 38 52 72 88 96 110 118 119 120 122 124 126 214-2017 1 - 2017 2 - 2017 3 Rudolf Bauer Peter Hylands Bruce Robinson 4 Appleby Offshore Incorporations (Cayman) Limited P. O. Box 31119
二零零八年度中期報告 2 3 17 19 20 22 23 25 46 49 51 54 2007 (%) 24,874 21,157 17.6% 2,375 1,942 22.3% 1,150 395 191.1% 8.9 3.2 178.1% 8.9 3.2 178.1% 9.6 6.8 41.18% 2 2008 3C 200824,874 17.6%1,150 191.1% 1,234 46.8%
2 2.1 A H A 2
CHINA RAILWAY GROUP LIMITED 390 1 1 2 2.1 A H 601390 00390 1 100070 www.crec.cn ir@crec.cn 2.2 100039 86-10-5187 8413 86-10-5187 8417 ir@crec.cn 69 A 2 3 3.1 3.1.1 2010 6 30 6 2009 2010 2009 2008 2007
5 4,818,561 4,731,563 (1,833,996) (1,804,632) 2,984,565 2,926,931 5 143,997 128,065 (1,975,832) (1,587,764) (280,144) (175,268) (214,237) (87,548) (15
Biostime International Holdings Limited 1112 4,818,561 4,731,563 1.8% 2,984,565 2,926,931 2.0% (EBITDA) 626,438 1,142,556 (45.2)% 293,321 806,786 (63.6)% 365,732 972,172 (62.4)% 0.41 1.34 (69.4)% 4,818.6
, ,171 (188,495) (213,231) 435, , ,024 30,302 (305,546) (319,034) (56,225) (69,190) (1,876) (1
GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 6896 2017 12 31 2016 12 31144.118.8%624.1 2016 12 31119.321.5%435.6 69.8% 2016 12 3182.9 43.8%106.2 2016 12 3141.540.3% 61.4 2017 12 31 0.06 2018 6 7-1 - 2017
untitled
ROYAL DELUXE HOLDINGS LIMITED 3789 ROYAL DELUXE HOLDINGS LIMITED 300,000,000216,000,000 84,000,000 30,000,0003,000,000 270,000,000186,000,000 84,000,000 0.671% 0.0027%0.005% 0.01 3789 32 342C 0.67 0.53
... ii I-1... II-1... III-1 i
CHINA SILVER GROUP LIMITED 815 7 23 24 25 45 48 ... ii... 1... 7... 24... 25... I-1... II-1... III-1 i ............................................. ii 14.07 Best Conduct Best Conduct Investments Limited
(Chi_H share).indb
2011 2012 3 22 181815 33 2011 2 4 6 8 10 44 52 61 87 88 97 101 103 106 250 251 252 253 256 2011 1 2 2011 279.20 58.81% 1.40%0.31 23.89%5.59 0.63% 0.06 357.29%86.842.23%0.35 20062009 2010 2011 2011 201183.60%
CHINA CHUNLAI EDUCATION GROUP CO., LTD. 中國春來教育集團有限公司 於開曼群島註冊成立的有限公司 股票代號 : 1969 2018 年度報告 2 41 3 49 5 96 6 100 7 147 16 151 21 2018 2 2004 2014/2015 29,673 2017/2018 45,210 2017 8 31460.9 2018 8 31487.8
Project Goat Milk_C_D&CT Cir.indb
AUSNUTRIA DAIRY CORPORATION LTD 1717 15% 88 EGM-1EGM-2 18317M48 ............................................................. 1........................................................ 6................................................
(Project North) Chi_.indb
ASIA MEMORIAL GROUP LIMITED 1438 ASIA MEMORIAL GROUP LIMITED 86 Asia Memorial Group Limited 19 123513 64102 133637 13 3863 310272 4 18317M 9810127. Asia Memorial Group Limited 0.01 (www.hkexnews.hk)(www.nirvana-asia-ltd.com)
untitled
China Development Bank International Investment Limited Interim Report 2016 China Development Bank International Investment Limited (Incorporated in the Cayman Islands with limited liability) (Stock Code:
2017 年報 2017 2 3 2017 7 33 55 65 75 80 85 87 89 90 91 148 Appleby Clifton House 75 Fort Street P.O. Box 1350 Grand Cayman KY1-1108 Cayman Islands 9 6 31 3105 Estera Trust (Cayman) Limited Clifton House
目 錄 公 司 資 料 釋 義 財 務 概 要 集 團 架 構 行 政 總 裁 報 告 管 理 層 討 論 及 分 析 董 事 及 高 級 管 理 層 簡 介 企 業 管 治 報 告 董 事 會 報 告 獨 立 核 數 師 報 告 經 審 核 財 務 報 表 2 3 5 7 9 13 23 29 4
China Dredging Environment Protection Holdings Limited : 871 871 2014 目 錄 公 司 資 料 釋 義 財 務 概 要 集 團 架 構 行 政 總 裁 報 告 管 理 層 討 論 及 分 析 董 事 及 高 級 管 理 層 簡 介 企 業 管 治 報 告 董 事 會 報 告 獨 立 核 數 師 報 告 經 審 核 財 務 報 表 2
2015 2 4 5 6 7 8 18 20 34 51 53 67 69 70 72 74 76 2015 2 1993 12 29 1994 7 1 1.00 3 H 1.00 571 [2009]124 % 2015 4 Beijing Urban Construction Design & Development Group Co., Limited H H 1599 H www.bjucd.com
( 7 01
2017 (http://www.ecinfohk.com)(http://www.hkgem.com) 7 01 3 4 5 6 13 17 25 33 44 49 50 52 53 55 96 02 33 43 89 7 9 21 2103-05 1 2206-19 99 11 62 1 2 2 3 D Estera Trust (Cayman) Limited, Clifton House,
2 3 8 22 30 31 32 33 35 36 38 77 % 2,452 1,983 24% 2,969 2,307 29% 1,103 974 13% (2) 45.0% 49.1% -4.1pp (4) 1,062 407 161% EBITDA (1) 1,556 1,219 28% EBITDA (2) 63.5% 61.5% 2.0pp (1) 472 422 12% (2) 19.2%
( ) :
() : 1198 2015 2 3 4 6 18 20 27 28 29 30 32 33 35 94 01 Donald H. Straszheim Donald H. Straszheim Donald H. Straszheim Donald H. Straszheim Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor,
<4D6963726F736F667420576F7264202D20C9F2D1F4D0CBC6EBD1DBD2A9B9C9B7DDD3D0CFDEB9ABCBBEB4B4D2B5B0E5CAD7B4CEB9ABBFAAB7A2D0D0B9C9C6B1D5D0B9C9CBB5C3F7CAE9A3A8C9EAB1A8B8E5B1A8CBCDC8D5C6DAA3BA32303134C4EA36D4C23230C8D5A3A92E646F63>
特 别 提 示 : 本 次 股 票 发 行 后 拟 在 创 业 板 市 场 上 市, 该 市 场 具 有 较 高 的 投 资 风 险 创 业 板 公 司 具 有 业 绩 不 稳 定 经 营 风 险 高 退 市 风 险 大 等 特 点, 投 资 者 面 临 较 大 的 市 场 风 险 投 资 者 应 充 分 了 解 创 业 板 市 场 的 投 资 风 险 及 本 公 司 所 披 露 的 风 险 因 素,
China Aluminum Cans Holdings Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l) 32 32 50 30% % % %... 114,719 57.9 133,882 56.5 142,784 52.1... 27,738 14.0 40,083 16.9 39,702 14.5... 24,901 12.6
untitled
2 3 4 7 14 18 20 29 30 31 32 33 34 72 1 , FCPA, FCCA, ACIS ACS, FCPA, FCCA, ACIS ACS 4th Floor P.O. Box 2804 George Town Grand Cayman Cayman Islands 18 28 2805 Butterfield Fund Services (Cayman) Limited
85,426,000 39,437,000 45,989, % 30,643,000 (79,340,000 ) 48,697, % 8,794,000 6,086,000 2,708, % 7,171,000 25,573,000 18,402,000 7
CEFC Hong Kong Financial Investment Company Limited 1520 39,437,000 85,426,000 53.8% 7,171,000 25,573,000 18,402,000 72.0% 18.2% 29.9% 44,808,000 10,502,000 34,306,000 326.7% 2.65 0.94 1 85,426,000 39,437,000
untitled
KML Technology Group Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) 32 [ ] KML Technology Group Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ][] [ ] [ ] 1%0.0027% 0.005% [ ] 0.01 [ ] [ ] [ ]
MediNet Group Limited 260,000,000 0.27 0.251% 0.0027% 0.005% 0.01 8161 342C 2016 5 25 0.27 0.25 www.hkexnews.hk www.medinetgroup.com 2016531 2016 5 24
MediNet Group Limited 260,000,000 0.27 0.251% 0.0027% 0.005% 0.01 8161 342C 2016 5 25 0.27 0.25 www.hkexnews.hk www.medinetgroup.com 2016531 2016 5 24 i 2016 1 2....5 25 www.medinetgroup.com www.hkexnews.hk
,152 31, , ,141 5,182 2,803 10,554 6,584 57,095 8, , , , , ,457 67, ,670 38,217 1,130,205 1
YIHAI INTERNATIONAL HOLDING LTD. 1579 2 017 12 3 1 2017 12 31 2016 2017 1,646.2 2016 1,088.0 51.3% 2017 611.8 2016 416.9 46.7% 2017 261.1 2016 186.7 39.9% 2017 260.7 2016 186.7 39.6% 2017 0.269 0.267 1
(I)... 2 (II)... 4 (III)... 6 (IV) (V) (VI) (VII) (VIII)
5 7.50 5880 2018 6 30 2018 6,650 2017 5.3% 2018 1,455 2018 752 2018 0.22 (I)... 2 (II)... 4 (III)... 6 (IV).... 7 (V)... 23 (VI)... 30 (VII).... 45 (VIII)... 93 1 (I) 2018 1 1 2018 6 30 Pioneer Cement
[] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% %0.005% 0.01 [] [] [] [] [] [] [][]32 342C [] [][] []
![[] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% %0.005% 0.01 [] [] [] [] [] [] [][]32 342C [] [][] []](/thumbs/91/106251375.jpg "[] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% %0.005% 0.01 [] [] [] [] [] [] [][]32 342C [] [][] []")
Mastermind Group Holdings Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) 1933 (j) (k) [] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% 0.0027%0.005% 0.01 [] [] [] [] [] [] [][]32
Livzon_C_2016 3rd EGM Cir.indb
LIVZON PHARMACEUTICAL GROUP INC.* 1513 (I) (II) 52122 2341 38 (www.hkexnews.hk)(www.livzon.com.cn) H 18322 24 H * .............................................................. 1........................................................
: 978 2014 2 3 5 12 18 19 21 22 23 168 200 17 1701 Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor, Royal Bank House 24 Shedden Road, George Town Grand Cayman KY1-1110 Cayman Islands 183
3 4-5 6-10 11-14 15-21 22-28 29-30 31 32 33 34 35-61 62 CPA, ACIS ACS Clifton House 75 Fort Street PO Box 1350 Grand Cayman KY1-1108 Cayman Islands 88 8 801 805 8 22 2201 3 150 164 3 http://www.world-linkasia.com
[ ] [ ] 52 [ ] [ ]
![[ ] [ ] 52 [ ] [ ]](/thumbs/43/23120224.jpg "[ ] [ ] 52 [ ] [ ]")
54 70 53 47 41 41 64 [ ] [ ] 52 [ ] [ ] 35 [ ] [ ] 53 55 62 44 47 54 63 43 54 70 33 53 0992 33003396 1157 600649 600754 A 900934 B 1025 8277 Fiat Industrial S.p.A. 1336 0354 1093 601928 47 13 Biosensors
2 4 6 8 15 19 21 22 23 24 26 28 30 Rudolf Bauer Peter Hylands Bruce Robinson (FCPA) Appleby Offshore Incorporations (Cayman) Limited P.O. Box 31119, Grand Pavilion Hibiscus Way, 802 West Bay Road Grand
China Rongzhong Financial Holdings Company Limited 100,000,000 10,000,000 90,000, % %0.005% Alliance Capital Partners Limited
3963 Alliance Capital Partners Limited Alliance Capital Partners Limited China Rongzhong Financial Holdings Company Limited 100,000,000 10,000,000 90,000,000 2.48 1% 0.0027%0.005% 0.01 3963 Alliance Capital
A Knowledgeable Man Wins The Whole World 2018 BOJUN EDUCATION COMPANY LIMITED () : 1758 2 3 5 7 8 28 56 61 71 92 96 97 99 100 102 155 17 2018 9 12 2018 9 110,173 1,391 852 2001 2001 6 2012 4 2018 9 2001
2 3 4 7 8 25 25 27 29 32 1313.22 33 34 34 35 35 35 35 36 37 38 40 41 42 44 45 84 1 China COSCO Holdings Company Limited China COSCO 1 3 300461 183 49 CEO ** * ** * ** H A H 1919 A 601919 H 183 18 1806-1807
GEM GEM GEM GEM GEM GEM GEM GEM GEM
Reach New Holdings Limited () : 8471 2017 GEM GEM GEM GEM GEM GEM GEM GEM GEM 1 2017 2 3 4 10 11 14 15 24 25 34 35 38 39 40 41 42 43 44 79 80 PO Box 1350 Clifton House 75 Fort Street Grand Cayman KY1 1108
2016 2 3 4 9 11 20 36 47 52 53 54 55 57 113 1 Mauffrey Benoit Jean Marie Mauffrey Benoit Jean Marie Mauffrey Benoit Jean Marie Mauffrey Benoit Jean Marie Mauffrey Benoit Jean Marie MBA, ACA, CPA (practising)
............................................................ 1........................................................ 4....................... 5.....
Tsui Wah Holdings Limited 1314 2015 8 14 3 50 2 16 20 (www.hkexnews.hk) 48 183 22 2015 7 14 ............................................................ 1........................................................
untitled
China Development Bank International Investment Limited Annual Report 2016 China Development Bank International Investment Limited (Incorporated in the Cayman Islands with limited liability) (Stock Code:
01 43662-09A 1..1
香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責, 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明, 並 明 確 表 示, 概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 上
00C Book.indb
VBG International Holdings Limited * 128,300,000 115,470,000 12,830,000 0.88 0.68 1%0.0027% 0.005% 0.01 8365 32 342C 0.88 0.68 www.hkexnews.hk www.vbg-group.com * i www.vbg-group.com www.hkexnews.hk (1)
2016 6 302015 2016 6 30 6 30 2016 2015 4 817,361 855,414 (682,150) (632,696) 135,211 222,718 4 9,174 2,306 (131) 897 250 (49,336) (48,034) (79,460) (7
EGL Holdings Company Limited 6882 2016 6 30 6 30 2016 2015 % 817,361 855,414-4.4 135,211 222,718-39.3 15,074 84,440-82.1 3.00 16.81 16.5% 26.0% 1.8% 9.9% 4.6% 26.5% 7-1 - 2016 6 302015 2016 6 30 6 30 2016
untitled
CK ASSET HOLDINGS LIMITED Cheung Kong Property Holdings Limited 826 2728 2948 20 5758 482 7 ................................................................. 1...........................................................
DLC Asia Limited * GEM 200,000, ,000,000 20,000, % %0.005% C
DLC ASIA LIMITED 8210 DLC Asia Limited * GEM 200,000,000 180,000,000 20,000,000 0.3 0.25 1% 0.0027%0.005% 0.01 8210 32 342C 0.30.25 www.hkexnews.hkwww.derivaasia.com 0.25 0.3 www.hkexnews.hkwww.derivaasia.com
Kangda International Environmental Company Limited 康達國際環保有限公司 於開曼群島註冊成立的有限公司 股份代號 6136 年度報告 2 4 6 18 24 40 56 61 62 64 66 68 164 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman
th Anniversary Little Sheep Group Limited : 968 2009 www.edico.com.hk 2 3 4 8 18 24 38 41 43 44 45 47 49 51 52 110 02 Nishpank Rameshbabu Kankiwala FCCA Cricket Square Hutchins Drive P.O. Box 2681 Grand
... 2... 3... 5... 6... 8... 13... 19.... 26... 41... 60... 62... 63... 64... 66... 68.... 71 1 2015
2015 Intime Retail (Group) Company Limited () : 1833 ... 2... 3... 5... 6... 8... 13... 19.... 26... 41... 60... 62... 63... 64... 66... 68.... 71 1 2015 2006 11 8 2007 3 20 199817 29172,895,674 201061
C160932347Ann.indd
Trony Solar Holdings Company Limited 2468 1 4 37,102 115,717 (38,349) (126,053) (1,247) (10,336) 5 15,609 5,844 (6,571) (7,636) (62,895) (57,313) (55,104) (69,441) 9 (2,946) (511) 7 (984) (58,050) (70,936)
................................................................ 1 1....................................................... 4 2.......................
WAI CHI HOLDINGS COMPANY LIMITED 1305 11 17 21 183 22 ................................................................ 1 1....................................................... 4 2..................................................
i
CHINA SEVEN STAR HOLDINGS LIMITED 245 (1) (2) (3) (4) (5) 6 41 42 43 44 68 57 73 EGM 1 EGM 3 48 183 22 ............................................................ i............................................................
2 3 5 7 11 42 56 81 83 99 101 103 104 106 108 111 221 222
Red Star Macalline Group Corporation Ltd. : 1528 2015 2 3 5 7 11 42 56 81 83 99 101 103 104 106 108 111 221 222 年 年 1528 O2O 報 告 28 126 177 11,660,468 18,000 2015 年 11.1%4.1% 2015 年 度 報 告 2 紅 Joseph Raymond
Regal International Airport Group Company Limited * 357 H *
Regal International Airport Group Company Limited * 357 H 6 29 30 31 32 50 68 82 * ............................................................... 1.........................................................
2 4 7 8 9 10 21 26 36 50 52 53 55 56 58
2 4 7 8 9 10 21 26 36 50 52 53 55 56 58 (ACCA, HKICPA) Clifton House 75 Fort Street P.O. Box 1350 Grand Cayman KY1-1108 Cayman Islands 465 103 www.chinauton.com 23 24 2404 2014 2 26 33 Appleby Trust (Cayman)
公 司 簡 介
波 司 登 國 際 控 股 有 限 公 司 ( 於 開 曼 群 島 註 冊 成 立 之 有 限 責 任 公 司 ) 股 份 代 號 : 3998 2014/15 年 報 公 司 簡 介 目 錄 2 4 8 29 39 43 57 59 61 63 65 66 68 146 148 財 務 摘 要 ( 除 另 有 指 明 外, 所 有 金 額 以 人 民 幣 千 元 為 單 位 ) 3 31 2015
和寶國際控股有限公司
1 2 3 4 6 11 13 18 20 21 23 24 26 27 60 * * ZUCHOWSKI Sam * * 10 2116 PO Box 309GT Ugland House South Church Street George Town, Grand Cayman Cayman Islands Butterfi eld Fund Services (Cayman) Limited
Intime Retail (Group) Company Limited () : 1833 2016 ... 2... 3... 5... 6... 7... 12... 17.... 22.... 37... 70... 82... 83... 88... 89... 90... 92... 94.... 97 1 2016 2006 11 8 2007 3 20 199818 29203,301,023
JINTIAN PHARMACEUTICAL GROUP LIMITED 500,000,000400,000,000 100,000,000 50,000,000 450,000,000350,000,000 100,000,000 4.23 1% 0.003%0.005% 0.001 2211
105;0(5 7/(94(*,
HUAXI HOLDINGS COMPANY LIMITED ( ) : 1689 2016 2 3 5 9 11 19 26 28 29 30 32 33 34 77 183 1906 07 Clifton House, P. O. Box 1350 Grand Cayman, KY1-1108 Cayman Islands Appleby Trust (Cayman) Ltd. Clifton
GRACE WINE HOLDINGS LIMITED ( ) :
GRACE WINE HOLDINGS LIMITED () : 8146 2018 GEM GEM GEM GEM GEM GEMGEM 2 4 6 14 20 35 64 77 82 83 84 86 87 89 160 Alec Peter Tracy Alec Peter Tracy 33 40 1 22 8 21 Cricket Square Hutchins Drive P.O. Box
% %
CHINA GREENFRESH GROUP CO., LTD. * 6183 2015 12 31 2015 12 31 2014 762.12216.45 39.67 276.47 78.5939.72 261.11 54.7226.51 37.8234.26 1 217.7342.64 24.36% 256.73 2014 37.50% 49.2 20.00 17.00 2 2015 12 31
2014 2 3 4 6 14 19 29 35 37 38 40 41 42 43 Clifton House 75 Fort Street P.O. Box 1350 Grand Cayman KY1-1108 Cayman Islands 199 18 1805 Appleby Trust (Cayman) Ltd. Clifton House 75 Fort Street P.O. Box
untitled
: 823 3 31 2011 2005 11 25 2011 3 31180 149 29 1,100 80,000 8% 33% 59% 96 97 99 144 194 196 199 02 04 06 10 14 18 22 52 60 63 66 66 81 86 89 99 100 101 102 103 104 105 2005 11 05/06 06/07 05 11 823 06
3 4 7 18 24 79 85 98 99 145 169 176 177 178
2014 年 度 報 告 3 4 7 18 24 79 85 98 99 145 169 176 177 178 13 12 AH102.5 2015 2 92015 2015AH HH 1,916,978,820H H HAH 11,501,700,0002,875,425,000.00H 479,244,705.0010,369,758,976.60 2 2014 IT FICC Banco Espírito
untitled
: 2628 2 3 6 7 10 29 36 39 50 54 70 92 96 97 98 100 102 104 105 107 217 1 1 1 2 China Life Insurance Company LimitedChina Life 16 86-10-63631244 86-10-66575112 ir@e-chinalife.com 16 86-10-63631068 86-10-66575112
i ii 1 2 3 4 6 10 12 122 123 126 128 129 131 132 133 134 135 275 14 14 17 30 35 42 45 48 54 56 62 64 277 287 288 66 78 92 106 112 114
二 零 一 四 年 年 報 i ii 1 2 3 4 6 10 12 122 123 126 128 129 131 132 133 134 135 275 14 14 17 30 35 42 45 48 54 56 62 64 277 287 288 66 78 92 106 112 114 释 义 及 重 大 风 险 提 示 2010 5 2011 72012 7 27 2011 7 2011